CCL22 Recombinant Rabbit mAb (SDT-1946-114-2)

CCL22, named macrophage-derived chemokine (MDC), is a vital chemokine predominantly produced by dendritic cells, macrophages and keratinocytes. It specifically binds to CCR4, mediating the chemotaxis of Th2 cells, regulatory T cells and eosinophils. Clinically, CCL22 can be quantitatively measured in serum, plasma, tissue fluid and cell culture supernatants through ELISA, chemiluminescence immunoassay, multiplex protein arrays and flow cytometry. These testing methods deliver reliable sensitivity and reproducibility, suitable for routine laboratory auxiliary detection and dynamic monitoring of patients. CCL22 detection owns prominent diagnostic value in multiple disease categories. For allergic and Th2-dominated inflammatory diseases including asthma, atopic dermatitis and allergic rhinitis, elevated circulating CCL22 directly reflects the degree of local allergic inflammation, supporting early auxiliary diagnosis and evaluating treatment efficacy. In autoimmune illnesses such as systemic lupus erythematosus, high CCL22 levels correlate with disease activity and organ involvement, helping clinicians judge lesion severity.

In oncology, tumor-secreted CCL22 recruits immunosuppressive regulatory T cells to remodel the tumor microenvironment. Its abnormal concentration assists auxiliary diagnosis of breast, gastric and lung cancers, and predicts tumor metastasis and unfavorable prognosis. Additionally, CCL22 serves as a marker for chronic inflammatory skin disorders and post-transplant immune rejection. One major limitation is insufficient disease specificity; clinicians must combine CCL22 with other biomarkers to improve diagnostic accuracy. In summary, quantitative CCL22 testing provides critical reference for identifying Th2 inflammation, assessing autoimmune activity, stratifying tumor risk and tracking therapeutic outcomes in diverse immune-related and malignant diseases.